Inclusion Criteria:

- age > 18 years

- gemcitabine-refractory, histologically confirmed pancreatic cancer (progression
during or within 6 months of first-line treatment)

- locally advanced or metastatic disease with measurable or non-measurable disease

- life expectancy of greater than 10 weeks

- prior treatment with investigational therapies including EGFR and VEGF antagonists is
allowed when administered>4 weeks prior to start of therapy

Exclusion Criteria:

- any serious uncontrolled medical condition

- prior radiation treatment is not allowed

- no prior chemotherapy within the previous 4 weeks

- known peripheral neuropathy > CTCAE v 3.0 grade 1; absence of the deep tendon
reflexes as the sole neurological abnormality does not render the patient ineligible

- known brain metastases

- lack of physical integrity of the upper GI tract, malabsorption syndrome, or
inability to take oral medication

- fertile women (<2 years after last menstruation) and men of childbearing potential
not willing to use effective contraception

- pregnancy or breast feeding